

## GREATER UPFRONT DISCOUNT ON ZOFRAN

### Effective April 1, 2005:

- > Earn a **greater upfront discount** on Zofran 32ml bags.  
The market share and performance rebate tiers on the **Zofran 32ml Bags** is reduced to a single tier (i.e. a clinic with a 60% or greater market share will earn a 10% rebate on the 32ml bags).
- > The contract pricing and performance rebate discounts on **Zofran's multi-dose vials** remain unchanged.  
The lowest market share tier for achieving a rebate is reduced from 65% to 60% for consistency with the bags.
- > Contract pricing on Hycamtin and Navelbine remains unchanged.
- > The market share measurement period and rebate period have been aligned.  
Effective April 1st, 2005 rebates will be paid 90 business days (rather than 30 business days) after the end of the quarter.



### Arixtra Added to GlaxoSmithKline Agreement with Performance Rebate

- > Arixtra Inj. PI Syringes are available in following quantities: 2.5mg/0.5ml 10s; 5mg/0.4ml 10s; 7.5mg/0.6ml 10s; 10mg/0.8ml 10s.
  - > Upfront discount of **10%** with a performance rebate up to **15%** available.
- Contact Oncology Associates at **888-732-7352** for more information about the GlaxoSmithKline agreement.



## NOVARTIS EXTENDS AGREEMENT FOR ZOMETA®

**Effective July 1, 2005**, the OA agreement for Zometa has been extended through **December 31, 2005**.

Zometa is offered to all OA members in good standing at a significant **discount of 4%**. The product is available in 4mg/5mL vials.

ZOMETA® Injection is indicated for the treatment of hypercalcemia of malignancy. ZOMETA® is also indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

Contact Oncology Associates at **888-732-7352** with any questions about the Novartis agreement. For more information about ZOMETA®, visit [www.zometa.com](http://www.zometa.com).



## SANDOSTATIN LAR® REBATES RELEASED

As part of the 2004 OA product agreement for Sandostatin LAR®, we are pleased to announce the release of November and December 2004 rebate checks. These checks were released on March 22, 2005 (November) and April 20, 2005 (December).

**PLEASE NOTE: There will be no more rebates for Sandostatin LAR®, as Novartis has discontinued this rebate agreement effective January 1, 2005.**

Contact Oncology Associates at 888-732-7352 with any questions regarding the rebates earned.



## VIDAZA AND INNOHEP AGREEMENT REMINDER

Oncology Associates would like to remind you of its agreement with Pharmion for Vidaza (azacitidine for injectable suspension). This product is available to all OA Members in good standing.

Vidaza is available in 100 mg vials and is indicated for the treatment of all five Myelodysplastic Syndrome (MDS) subtypes.

### Innohep Agreement Reminder

Oncology Associates would also like to remind you of its contract for Innohep® (tinzaparin sodium for injection) with Pharmion Corporation. Innohep® is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin®).

Innohep® is currently available through FloridaInfusion Services. Contact FIS directly at **800-624-0152** to place an order.

For more information on Vidaza and Innohep, visit Pharmion's web site at [pharmion.com](http://pharmion.com) or contact Pharmion directly for complete prescribing information at **1-866-PHARMION**. Please call Oncology Associates at **888-732-7352** with any questions regarding these agreements.

